← Back to headlines
Molecular Partners Presents on DLL3-Targeting Radio-DARPin MP0712 in Phase 1 Trials
Molecular Partners held presentations at ASCO and SNMMI 2026 regarding their DLL3-Targeting Radio-DARPin MP0712, which is currently dosing patients in Phase 1 clinical trials.
30 May, 12:00 — 30 May, 12:00
